ASND Stock Analysis: Buy, Sell, or Hold?
ASND - Ascendis Pharma A/S American Depositary Shares
$228.00
-2.83 (-1.23%)
▼
5d:
+4.56%
30d:
-5.53%
90d:
+2.76%
BUY
HIGH Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When ASND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ASND trading at deep discount. Market pricing in -8.4% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: ASND trading at deep discount. Market pricing in -8.4% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$163.05
Based on -6.8% avg growth
INTRINSIC VALUE TODAY
$101.24
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ASND is currently trading at $228.00, which is considered fair relative to its 30-day fair value range of $215.05 to $239.11. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.2) compared to its historical average (31.5). Remarkably, the market is currently pricing in an annual earnings decline of 8.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ASND is showing sideways momentum. Immediate support is located at $203.80, while resistance sits at $237.00.
Market Sentiment: ASND has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $292.38 (+28.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ASND is showing sideways momentum. Immediate support is located at $203.80, while resistance sits at $237.00.
Market Sentiment: ASND has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $292.38 (+28.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$215.05 -
$239.11
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 28.2% below Wall St target ($292.38)
Trading Range Analysis
30-Day Trading Range
$215.05 -
$239.11
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$203.80
Resistance Level
$237.00
Current Trend
Sideways
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.17
Wall Street Target
$292.38
(+28.2%)
Revenue Growth (YoY)
144.3%
Profit Margin
57.3%
Valuation Discount vs History
-8.4% cheaper
PE vs Historical
24.2 vs 31.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.4%
(market-implied from PE analysis)
1-Year Target
$208.85
(-8%)
2-Year Target
$191.30
(-16%)
3-Year Target
$175.24
(-23%)
3-Yr Target (if PE normalizes)
(PE: 24→32)
$228.36
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.2, Growth: -17.6%)
$166.21
(+-27%)
Base:
(SPY PE: 21.8, Growth: -17.6%)
$149.77
(-34%)
Bear:
(PE: 18.5, Growth: -17.6%)
$127.30
(-44%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (24x PE) as earnings recover.
Trailing PE: 26.36 | Current EPS (TTM): $8.79
Bull Case
$273.49
(+20%)
Analyst growth 7.3%, PE expands to 29.0
Base Case
$248.63
(+9%)
Market implied 7.3%, PE stable at 26.4
Bear Case
$157.55
(-31%)
Severe decline -20.0%, PE contracts to 22.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.2 to 31.5
Stabilization Target:
$297.12
(+30.3%)
PE Expansion Potential:
+30.3%
Share & Embed Analysis
Last updated: June 23, 2026 8:36 AM ET
Data refreshes hourly during market hours. Next update: 9:36 AM
Data refreshes hourly during market hours. Next update: 9:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ASND showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 64 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 60 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
